Atlas Trials

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

Clinical trial NCT07222384 · COMPLETED

Trial details

NCT number
NCT07222384
Sponsor
BioNTech SE
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
COVID-19SARS-COV-2 Infection
Start date
2025-10-30
Primary completion
2026-07-24
Enrollment
344

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.